A Phase IV Safety and Efficacy of VI-0521 in Obese Adolescents
Status:
Completed
Trial end date:
2021-04-16
Target enrollment:
Participant gender:
Summary
This study is being conducted to assess weight loss efficacy, as determined by changes in
body mass index (BMI), and safety of VI-0521 (Qsymia®) or placebo, taken for 56 weeks
accompanied by a lifestyle modification program in obese adolescents age 12-16 years.